Assessment of Relationship Between Expression of Survivin Protein and Histopathology Diagnosis and Malignancy Severity in Colon Specimen

  • Amin Jourabchin
  • Tahereh Mazoochi
  • Hamed Haddad Kashani
  • Tahereh KhamechianEmail author
Original Research



Survivin is a member of the inhibitor of an apoptosis protein family that has been shown to inhibit apoptosis, promote cell proliferation and enhance angiogenesis. In this study, the survivin protein expression in normal, colon polyp, and adenocarcinoma tissues was investigated.


Immunohistochemical staining for nuclear survivin was carried out on 45 normal colon tissue samples, 38 samples of a colonic polyp, and 37 cases of colon adenocarcinoma operated by colonoscopy or colectomy. The percentages of cells that expressed survivin were classified qualitatively into four categories (0, 1+, 2+, and 3+) based on the intensity of staining and the percentage of cells. An area of samples with colon polyp diagnosis or colon adenocarcinoma that had no microscopic pathology was considered as normal tissues.


Survivin protein expression was negative in all cases of normal colon tissue samples while it was expressed in 31 out of 38 colon polyp specimens (81.5%) and in 35 out of 37 (94.5%) colon adenocarcinoma samples. Amount of expression in the colon adenocarcinoma (p < 0.001) was significantly higher than the amount of expression in the colon polyp. There was not a significant correlation between the survivin protein expression and the low and high grade adenocarcinoma (p = 0.874).


Survivin protein was not expressed in normal colon tissues and its amount was higher in the colonic adenocarcinoma compared to the colon polyp. Due to the variations in the intensity of expression in colon polyp (changing from negative to + 3), this marker cannot be used for differentiating the polyp from the adenocarcinoma.


Survivin Immunohistochemistry Histopathology Colon Tumor Adenocarcinoma 



This work was supported by Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran.

Availability of Data and Materials

The dataset used in this study is available with the authors and can be made available upon request.

Authors’ Contributions

All the authors participated in the study design. TK, AJ, and TM collected and documented the data and assisted in preliminary data analysis. TK, AJ, and TM wrote the initial draft. HHK participated in draft revision, data analysis, and editing of the final draft.


The financial support for the current research was provided by Research Deputy of Kashan University of Medical Sciences, Kashan, Iran.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval and Consent to Participate

All procedures performed in the study involving human were in accordance with the 1964 Helsinki declaration and ethical standards of the institutional and national research committee of Kashan University of Medical Sciences. The protocol was approved by the research committee of Kashan University of Medical Sciences, Kashan, Iran.


  1. 1.
    Rosai J. Rosai and Ackerman’s surgical pathology-10th ed. New York, NY: Mosby; 2011. p. 731–802.Google Scholar
  2. 2.
    Shintani M, et al. Immunohistochemical analysis of cell death pathways in gastrointestinal adenocarcinoma. Biomed Res. 2011;32(6):379–86.CrossRefGoogle Scholar
  3. 3.
    Kumar V, et al. Robbins and Cotran pathologic basis of disease. Philadelphia: Elsevier Saunders; 2005.Google Scholar
  4. 4.
    Cardona MK, Knudsen B. Expression and regulation of survivin in prostate cancer. McNair J. 2011;7(1):5.Google Scholar
  5. 5.
    Eslami M, et al. Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy. Springerplus. 2016;5(1):621.CrossRefGoogle Scholar
  6. 6.
    Mita AC, et al. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14(16):5000–5.CrossRefGoogle Scholar
  7. 7.
    Wei Y, Fan T, Yu M. Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin. 2008;40(4):278–88.CrossRefGoogle Scholar
  8. 8.
    Mobahat M, Narendran A, Riabowol K. Survivin as a preferential target for cancer therapy. Int J Mol Sci. 2014;15(2):2494–516.CrossRefGoogle Scholar
  9. 9.
    Chiou S-K, Jones MK, Tarnawski AS. Survivin-an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit. 2003;9(4):PI25–9.Google Scholar
  10. 10.
    Wheatley SP. Nuclear survivin: cellular consequences and therapeutic implications. 2011:InTech.
  11. 11.
    Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67(13):5999–6002.CrossRefGoogle Scholar
  12. 12.
    Li F, et al. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer. 2005;114(4):509–12.CrossRefGoogle Scholar
  13. 13.
    Vischioni B, et al. Nuclear localization of survivin is a positive prognostic factor for survival in advanced non-small-cell lung cancer. Ann Oncol. 2004;15(11):1654–60.CrossRefGoogle Scholar
  14. 14.
    Kitamura H, et al. Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch. 2013;462(1):101–7.CrossRefGoogle Scholar
  15. 15.
    Rexhepaj E, et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer. BMC Cancer. 2010;10(1):639.CrossRefGoogle Scholar
  16. 16.
    Compton CC, et al. Prognostic factors in colorectal cancer: College of American Pathologists consensus statement 1999. Arch Pathol Lab Med. 2000;124(7):979–94.Google Scholar
  17. 17.
    Piroozmand A, Kashani HH, Zamani B. Correlation between Epstein-Barr virus infection and disease activity of systemic lupus erythematosus: a cross-sectional study. Asian Pac J Cancer Prev. 2017;18(2):523.Google Scholar
  18. 18.
    Saba MA, et al. Diagnostic value of neuron-specific enolase (NSE) and cancer antigen 15-3 (CA 15-3) in the diagnosis of pleural effusions. Asian Pac J Cancer Prev. 2017;18(1):257.Google Scholar
  19. 19.
    Ferdosian M, et al. Identification of immunotopes against Mycobacterium leprae as immune targets using PhDTm-12mer phage display peptide library. Trop J Pharm Res. 2015;14(7):1153–9.CrossRefGoogle Scholar
  20. 20.
    Hosseini ES, et al. Purification of antibacterial CHAP K protein using a self-cleaving fusion tag and its activity against methicillin-resistant Staphylococcus aureus. Probiotics Antimicrob Proteins. 2016;8(4):202–10.CrossRefGoogle Scholar
  21. 21.
    Haddad Kashani H, et al. A novel chimeric endolysin with antibacterial activity against methicillin-resistant Staphylococcus aureus. Front Cell Infect Microbiol. 2017;7:290.CrossRefGoogle Scholar
  22. 22.
    Kashani HH, Moniri R. Expression of recombinant pET22b-LysK-cysteine/histidine-dependent amidohydrolase/peptidase bacteriophage therapeutic protein in Escherichia coli BL21 (DE3). Osong Public Health Res Perspect. 2015;6(4):256–60.CrossRefGoogle Scholar
  23. 23.
    Adamkov M, et al. Relationship of mismatch repair proteins and survivin in colon polyps and carcinomas. Acta Histochem. 2014;116(6):1007–14.CrossRefGoogle Scholar
  24. 24.
    Nikzad H, et al. Expression of galectin-8 on human endometrium: molecular and cellular aspects. Iran J Reprod Med. 2013;11(1):65.Google Scholar
  25. 25.
    Kashani HH, et al. Expression of galectin-3 as a testis inflammatory marker in vasectomised mice. Cell J (Yakhteh). 2013;15(1):11.Google Scholar
  26. 26.
    Kamani M, et al. Protective effect of Lepidium sativum seed extract on histopathology and morphology of epididymis in diabetic rat model/Efecto protector de extracto de semilla Lepidium sativum sobre la histopatologia y morfologia del epididimo en modelo de rata diabetica. Int J Morphol. 2017;35(2):603–11.CrossRefGoogle Scholar
  27. 27.
    Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087–98.CrossRefGoogle Scholar
  28. 28.
    Mazoochi T, et al. The effect of melatonin on expression of p53 and ovarian preantral follicle development isolated from vitrified ovary. Comp Clin Pathol. 2018;27(1):83–8.CrossRefGoogle Scholar
  29. 29.
    Shariat SF, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004;100(4):751–7.CrossRefGoogle Scholar
  30. 30.
    Rodríguez-Berriguete G, et al. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate. BMC Cancer. 2010;10(1):18.CrossRefGoogle Scholar
  31. 31.
    Shintani M, et al. Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp Pathol. 2013;6(12):2919.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Anatomical Sciences Research CenterKashan University of Medical SciencesKashanIran
  2. 2.Gametogenese Research CenterKashan University of Medical SciencesKashanIran

Personalised recommendations